Roche

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Roche and other ETFs, options, and stocks.

About RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments.

CEO

Thomas Schinecker

CEOThomas Schinecker

Employees

112,774

Employees112,774

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1896

Founded1896

Employees

112,774

Employees112,774

RHHBY Key Statistics

Market cap

356.04B

Market cap356.04B

Price-Earnings ratio

22.76

Price-Earnings ratio22.76

Dividend yield

1.80%

Dividend yield1.80%

Average volume

1.36M

Average volume1.36M

High today

$55.87

High today$55.87

Low today

$54.74

Low today$54.74

Open price

$55.60

Open price$55.60

Volume

950.12K

Volume950.12K

52 Week high

$60.85

52 Week high$60.85

52 Week low

$39.50

52 Week low$39.50

RHHBY News

Seeking Alpha 6h

Roche, Ionis succeed in late-stage trial for kidney disease therapy

Ionis Pharmaceuticals (IONS) and Roche (RHHBY) announced on Wednesday that their RNA-targeting therapy sefaxersen succeeded in a late-stage trial for patients w...

TipRanks 9h

Roche’s Genentech reports ‘positive’ results from Phase 3 Imagination study

Genentech, a member of the Roche (RHHBY) Group, announced positive prespecified interim results from the ongoing Phase III Imagination study evaluating investig...

Investing.com 10h

Roche’s sefaxersen shows positive results in kidney disease trial - Investing.com

...

Analyst ratings

54%

of 24 ratings

Buy

54.2%

Hold

37.5%

Sell

8.3%

More RHHBY News

TipRanks 1d

Zealand announces initiation of registrational Phase 3 ZUPREME program

Zealand Pharma (ZLDPF) announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelin...

The Wall Street Journal 2d

Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial

Roche said there was a meaningful proportion of patients reaching normalized glucose levels within less than a year of treatment. Xavier Galiana / Agence France...

TipRanks 2d

Roche reports European Commission approves Susvimo for nAMD

Roche (RHHBY) announced that the European Commission has approved Susvimo for the treatment of neovascular age-related macular degeneration, or nAMD. “The Europ...

TipRanks 5d

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents

Roche (RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Ocrevus intravenous...

Seeking Alpha 6d

Roche succeeds in late-stage study for Lunsumio regimen in follicular lymphoma

Roche’s (RHHBY) Genentech unit on Thursday announced a late-stage trial success for a combination regimen containing its bispecific antibody, Lunsumio, against...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.